Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck and Serum Institute of India have joined hands to develop and commercialize pneumococcal conjugate vaccine (PCV) for the developing nations.
Subscribe to our email newsletter
Both the companies are expected to establish a Product Advisory Committee to manage the activities that are required to develop and seek approval for PCV and to pursue World Health Organization (WHO) prequalification.
The tie up allows Merck to market PCV in some of the territories and Serum in other territories.
Under the contract, Merck and Serum will jointly contribute to the development and manufacture of PCV.